MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

MC

530.3

+7.21%↑

SANES

6.742

+1.63%↑

BNP

79.04

+2.21%↑

DB1.DE

279.4

-3.39%↓

CABK

7.336

+1.21%↑

Search

Sartorius Stedim Biotech.

Closed

SectorFinance

203.1 0.64

Overview

Share price change

24h

Current

Min

196.55

Max

203.6

Key metrics

By Trading Economics

Income

75M

115M

Sales

-6.7M

745M

P/E

Sector Avg

100.566

24.507

EPS

1.16

Dividend yield

0.33

Profit margin

15.498

Employees

9,961

EBITDA

124M

256M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.09% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.33%

4.35%

Next Earnings

22 Jul 2025

Market Stats

By TradingEconomics

Market Cap

4.2B

21B

Previous open

202.46

Previous close

203.1

News Sentiment

By Acuity

34%

66%

93 / 540 Finance

Technical Score

By Trading Central

Confidence

Bullish Evidence

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

11 May 2025, 23:48 UTC

Earnings
Acquisitions, Mergers, Takeovers

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

11 May 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

11 May 2025, 23:45 UTC

Market Talk

Oil Rises Amid Improved Market Mood -- Market Talk

11 May 2025, 23:38 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Aristocrat Has Significant Firepower for M&A -- Market Talk

11 May 2025, 23:36 UTC

Market Talk

Global Markets Uncertain About US-China Trade News -- Market Talk

11 May 2025, 23:35 UTC

Market Talk

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

11 May 2025, 23:33 UTC

Earnings
Acquisitions, Mergers, Takeovers

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

11 May 2025, 23:32 UTC

Top News

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

11 May 2025, 22:44 UTC

Market Talk

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

11 May 2025, 22:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

11 May 2025, 20:19 UTC

Top News

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

11 May 2025, 16:00 UTC

Top News

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

11 May 2025, 11:00 UTC

Top News

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

11 May 2025, 08:00 UTC

Top News

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

11 May 2025, 01:00 UTC

Top News

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

11 May 2025, 01:00 UTC

Top News

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

10 May 2025, 21:54 UTC

Top News

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10 May 2025, 17:12 UTC

Top News

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10 May 2025, 15:41 UTC

Top News

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

10 May 2025, 12:00 UTC

Top News

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10 May 2025, 09:30 UTC

Top News

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

10 May 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10 May 2025, 03:52 UTC

Top News

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9 May 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9 May 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9 May 2025, 21:37 UTC

Top News

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9 May 2025, 21:10 UTC

Top News

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9 May 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 May 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9 May 2025, 20:42 UTC

Top News

Stocks Get a Break From Trade Chaos -- WSJ

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

18.09% upside

12 Months Forecast

Average 239.13 EUR  18.09%

High 250 EUR

Low 210 EUR

Based on 8 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

202.7 / 211.7Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

93 / 540 Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.